Used in the treatment of relapsed or refractory acute myeloid leukemia (AML) with a specific IDH2 mutation. It works by inhibiting the mutated IDH2 enzyme, which helps reduce the production of an oncometabolite that blocks normal blood cell differentiation. This allows immature blood cells to mature properly and decreases the number of leukemia cells. Currently under clinical investigation, it shows promise as a targeted therapy for patients with this genetic subtype of AML, offering a potential oral treatment option with fewer side effects compared to traditional chemotherapy.